Oruka Therapeutics’ (ORKA) Outperform Rating Reaffirmed at Wedbush

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a note issued to investors on Thursday, Benzinga reports. They presently have a $165.00 target price on the stock. Wedbush’s price objective suggests a potential upside of 83.48% from the stock’s previous close.

A number of other brokerages have also issued reports on ORKA. Weiss Ratings raised Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Guggenheim reiterated a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Thursday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $180.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $133.00.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $89.93 on Thursday. The firm has a market capitalization of $5.95 billion, a PE ratio of -44.30 and a beta of -0.34. Oruka Therapeutics has a 52 week low of $14.89 and a 52 week high of $115.51. The business’s 50-day simple moving average is $96.79 and its 200-day simple moving average is $75.32.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Research analysts forecast that Oruka Therapeutics will post -2.42 earnings per share for the current year.

Insider Transactions at Oruka Therapeutics

In related news, SVP Arjun Agarwal sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the completion of the transaction, the senior vice president directly owned 15,312 shares in the company, valued at $1,633,177.92. The trade was a 39.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Klein sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the completion of the sale, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at approximately $84,996,011.40. This represents a 7.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 122,950 shares of company stock worth $11,528,806. 23.49% of the stock is owned by company insiders.

Institutional Trading of Oruka Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new stake in shares of Oruka Therapeutics during the 2nd quarter worth $474,916,000. Jupiter Topco LLC acquired a new position in Oruka Therapeutics during the second quarter worth about $130,968,000. Bank of America Corp DE bought a new position in Oruka Therapeutics during the 2nd quarter worth $33,578,000. Braidwell LP acquired a new position in shares of Oruka Therapeutics during the second quarter valued at about $26,473,000. Finally, Atika Capital Management LLC purchased a new stake in Oruka Therapeutics in the 1st quarter valued at about $11,277,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics News Roundup

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: ORKA-001 produced deepening psoriasis responses without additional dosing after Week 4. By Week 28, the PASI 100 response rate reached 71.4% and the PASI 90 rate reached 87.3%, supporting the potential for durable disease control from the half-life-extended IL-23p19 antibody. Oruka Therapeutics Week 28 Data Announcement
• Positive Sentiment: Patients who crossed over from placebo also achieved PASI 90 and PASI 100 response rates comparable to those initially treated with ORKA-001, while the therapy maintained a favorable safety and tolerability profile through Week 28. EVERLAST-A Week 28 Results
• Neutral Sentiment: The results remain from a mid-stage Phase 2a study, so investors still need larger and later-stage data to assess efficacy, durability, safety, and the drug’s competitiveness against established psoriasis treatments. The company expects full 52-week EVERLAST-A data in December 2026 and EVERLAST-B Week 16 data in the fourth quarter of 2026. What the Phase 2a Data Means for Shareholders
• Negative Sentiment: Despite the improving response rates, ORKA shares fell as investors appeared to treat the update as insufficient for further upside, potentially reflecting profit-taking and high expectations already embedded in the stock. Reports specifically highlighted that the shares declined despite the deepening responses. Oruka Shares Fall Despite Deepening Week 28 Responses

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.